Shouldn't enantiomeric purity be included in the minimum information about a bioactive entity? Response from the MIABE group
Orchard, S., Al-Lazikani, B., Bryant, S., Clark, D., Calder, E., Dix, I., Engkvist, O., Forster, M., Gaulton, A., Gilson, M., +16 more...Glen, R., Grigorov, M., Hammond-Kosack, Kim
, Harland, L., Hopkins, A., Larminie, C., Lynch, N., Mann, R. K., Murray-Rust, P., Lo Piparo, E., Southan, C., Steinbeck, C., Wishart, D., Hermjakob, H., Overington, J. and Thornton, J.
(2012)
Shouldn't enantiomeric purity be included in the minimum information about a bioactive entity? Response from the MIABE group.
Nature Reviews Drug Discovery, 10.
p. 661.
10.1038/nrd3503-c2
, Harland, L., Hopkins, A., Larminie, C., Lynch, N., Mann, R. K., Murray-Rust, P., Lo Piparo, E., Southan, C., Steinbeck, C., Wishart, D., Hermjakob, H., Overington, J. and Thornton, J.
(2012)
Shouldn't enantiomeric purity be included in the minimum information about a bioactive entity? Response from the MIABE group.
Nature Reviews Drug Discovery, 10.
p. 661.
10.1038/nrd3503-c2
[Reply to Letter]
-
picture_as_pdf - nrd3503-c2.pdf
-
subject - Published Version
-
- Available under Creative Commons: Attribution 4.0
Downloads